Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Bodurka, Charlotte Sun (2006)
Quality of Life and Sexual Functioning
C. Taylor, K. Basen-Engquist, E. Shinn, D. Bodurka (2004)
Predictors of sexual functioning in ovarian cancer patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 5
J. Sloan, A. Dueck (2004)
Issues for Statisticians in Conducting Analyses and Translating Results for Quality of Life End Points in Clinical TrialsJournal of Biopharmaceutical Statistics, 14
F. Cartwright-Alcarese (1995)
Addressing sexual dysfunction following radiation therapy for a gynecologic malignancy.Oncology nursing forum, 22 8
S. Young-McCaughan (1996)
Sexual functioning in women with breast cancer after treatment with adjuvant therapy.Cancer nursing, 19 4
S. Senn (1993)
Cross-over trials in clinical research
A. Clayton, E. McGarvey, G. Clavet, L. Piazza (1997)
Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ).Psychopharmacology bulletin, 33 4
J. Ballenger (2007)
Treatment with percutaneous testosterone gel in postmenopausal women with decreased libido-effects on sexuality and psychological general well-beingNathorst-Böös J, Flöter A, Jarkander-Rolff M, et al (Karolinska Hosp, Stockholm; Huddinge Univ Hosp, Sweden) Maturitas 53:11–18, 2006§Yearbook of Psychiatry and Applied Mental Health
J. Shell (2002)
Evidence-based practice for symptom management in adults with cancer: sexual dysfunction.Oncology nursing forum, 29 1
M. Wilmoth, Portia Botchway (1999)
Psychosexual implications of breast and gynecologic cancer.Cancer investigation, 17 8
B. Andersen (1985)
Sexual functioning morbidity among cancer survivors. Current status and future research directionsCancer, 55
S. Davis, Rebecca Goldstat, Mary-Anne Papalia, Sonal Shah, J. Kulkarni, S. Donath, R. Bell (2006)
Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trialMenopause, 13
Rebecca Goldstat, E. Briganti, J. Tran, R. Wolfe, S. Davis (2003)
Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal womenMenopause, 10
Samantha Litzinger, K. Gordon (2005)
Exploring Relationships Among Communication, Sexual Satisfaction, and Marital SatisfactionJournal of Sex & Marital Therapy, 31
J. Ware (2000)
SF-36 Health Survey UpdateSpine, 25
J. Buster, S. Kingsberg, O. Aguirre, Candace Brown, Jeffrey Breaux, A. Buch, C. Rodenberg, K. Wekselman, P. Casson (2005)
Testosterone Patch for Low Sexual Desire in Surgically Menopausal Women: A Randomized TrialObstetrics & Gynecology, 105
Christina Thors, J. Broeckel, P. Jacobsen (2001)
Sexual functioning in breast cancer survivors.Cancer control : journal of the Moffitt Cancer Center, 8 5
G. Braunstein, D. Sundwall, M. Katz, J. Shifren, J. Buster, J. Simon, G. Bachman, O. Aguirre, J. Lucas, C. Rodenberg, A. Buch, N. Watts (2005)
Safety and Efficacy of a Testosterone Patch for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women: A Randomized, Placebo-Controlled TrialJAMA Internal Medicine, 165
R. Basson (2004)
Recent advances in women’s sexual function and dysfunctionMenopause, 11
J. Simon, G. Braunstein, L. Nachtigall, W. Utian, M. Katz, Sam Miller, A. Waldbaum, C. Bouchard, C. Derzko, A. Buch, C. Rodenberg, J. Lucas, S. Davis (2005)
Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder.The Journal of clinical endocrinology and metabolism, 90 9
S. Curran, M. Andrykowski, J. Studts (1995)
Short Form of the Profile of Mood States (POMS-SF): Psychometric Information.Psychological Assessment, 7
Nams Continuing Medical Education Activity
J. Nathorst-böös, A. Flöter, M. Jarkander-Rolff, K. Carlström, B. Schoultz (2006)
Treatment with percutanous testosterone gel in postmenopausal women with decreased libido--effects on sexuality and psychological general well-being.Maturitas, 53 1
G. Greendale, L. Petersen, Laura Zibecchi, P. Ganz (2001)
Factors related to sexual function in postmenopausal women with a history of breast cancerMenopause, 8
J. Sloan, D. Cella, R. Hays (2005)
Clinical significance of patient-reported questionnaire data: another step toward consensus.Journal of clinical epidemiology, 58 12
J. Shifren, Glenn Braunstein, James Simon, Peter Casson, J. Buster, G. Redmond, Burki Re, Elizabeth Ginsburg, Raymond Rosen, Leiblum, K. Caramelli, Norman Mazer (2000)
Transdermal testosterone treatment in women with impaired sexual function after oophorectomy.The New England journal of medicine, 343 10
A. Clayton, E. McGarvey, G. Clavet (1997)
The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity.Psychopharmacology bulletin, 33 4
G. McPhail, Lorraine Smith (2000)
Acute Menopause Symptoms During Adjuvant Systemic Treatment for Breast Cancer: A CASE–CONTROL STUDYCancer Nursing, 23
B. Andersen, M. Elliot (1993)
Sexuality for women with cancer: Assessment, theory, and treatmentSexuality and Disability, 11
J. Ware, C. Sherbourne (1992)
The MOS 36-Item Short-Form Health Survey (SF-36)
BackgroundDecreased libido is one of several changes in sexual function that are often experienced by female cancer patients. Transdermal testosterone therapy has been associated with increased libido among estrogen-replete women who report low libido.MethodsIn a phase III randomized, placebo-controlled crossover clinical trial, we evaluated whether transdermal testosterone would increase sexual desire in female cancer survivors. Postmenopausal women with a history of cancer and no current evidence of disease were eligible if they reported a decrease in sexual desire and had a sexual partner. Eligible women were randomly assigned to receive 2% testosterone in Vanicream for a testosterone dose of 10 mg daily or placebo Vanicream for 4 weeks and were then crossed over to the opposite treatment for an additional 4 weeks. The primary endpoint was sexual desire or libido, as measured using the desire subscales of the Changes in Sexual Functioning Questionnaire, as assessed at baseline and at the end of 4 and 8 weeks of treatment. Serum levels of bioavailable testosterone were measured at the same times. All statistical tests were two-sided.ResultsWe enrolled 150 women. Women who were on active testosterone cream had higher serum levels of bioavailable testosterone than women on placebo (mean change from baseline, testosterone versus placebo, week 4, 11.57% versus 0%, difference 11.57%, 95% confidence interval [CI] 8.49% to 14.65%; week 8, 10.21% versus 0.28%, difference 9.92%, 95% CI 5.42% to 14.42%; P<.001 for all). However, the average intrapatient libido change from baseline to weeks 4 and 8 was similar on both arms.ConclusionIncreased testosterone level did not translate into improved libido, possibly because women on this study were estrogen depleted.
JNCI: Journal of the National Cancer Institute – Oxford University Press
Published: May 2, 2007
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.